Publications by authors named "R C Bodine"
Article Synopsis
- Theca cells play crucial roles in ovarian follicle growth and maturation, providing necessary structural, metabolic, and steroid-producing support.
- Researchers conducted single cell multi-omics analysis to understand the origins and differentiation of various theca cell subtypes in human antral stage follicles.
- They identified three specific types of theca cells—structural, androgenic, and perifollicular—along with a progenitor cell, contributing to a better understanding of ovarian development and potential implications for diagnosing or treating ovarian disorders.
In Brief: Xenografts of human ovarian cortical tissue provide a tractable model of heterotopic autotransplantation that is used for fertility preservation in patients undergoing ablative chemo/radiotherapy. This study describes the behavior of hundreds of xenografts to establish a framework for the clinical function of ovarian cortex following autotransplantation over short- and long-term intervals.
Abstract: More than 200 live births have been achieved using autotransplantation of cryopreserved ovarian cortical fragments, yet challenges remain to be addressed.
Objective: To measure the influence of exogenous insulin-like growth factor 1 (IGF1) on follicle growth and maturation in human ovarian cortical xenografts.
Design: Xenotransplantation model.
Setting: University-based research laboratory.
Anti-Müllerian hormone (AMH) is produced by growing ovarian follicles and provides a diagnostic measure of reproductive reserve in women; however, the impact of AMH on folliculogenesis is poorly understood. We cotransplanted human ovarian cortex with control or AMH-expressing endothelial cells in immunocompromised mice and recovered antral follicles for purification and downstream single-cell RNA sequencing of granulosa and theca/stroma cell fractions. A total of 38 antral follicles were observed (19 control and 19 AMH) at long-term intervals (>10 weeks).
View Article and Find Full Text PDFPharmacist-Driven Step-Down of Long-Term Proton-Pump Inhibitor Therapy.
Sr Care Pharm
September 2019
To evaluate the appropriateness of proton-pump inhibitor (PPI) prescribing and reduce the number of outpatients on long-term PPI therapy, defined as greater than or equal to one year.
Phase I was retrospective and evaluated the appropriateness of PPI prescribing. Phase II was prospective and involved implementation of a pharmacist-driven PPI step-down protocol.